A2A Pharma Competitors and Similar CompaniesClear all
A2A Pharma's competitors and similar companies include Immunai, Cipla, CSL Behring and Biogen.
 A2A Pharma A2A Pharma is a company that designs small-molecule therapeutics to treat cancer and antibiotic-resistant bacterial infections. |  Immunai Immunai is a biotechnology company specializing in immune cell data analysis for drug development. |  Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | ||
Founding Date | Founding Date 2016 | Founding Date 2018 | Founding Date 1935 | Founding Date 1904 | Founding Date 1978 |
Type | Type Private | Type Private | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations New York, US HQ Cambridge, US | Locations New York, US HQ Prague, CZ Ness Ziona, IL Tel Aviv, IL Zurich, CH | Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more | Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more |
Employees | Employees 11 | Employees 1873% increase | Employees 27,764 | Employees 7,5692% decrease | Employees 7,605 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 26.7 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ₹277.1b (FY, 2026) | Revenue (est.) $7.9b (FY, 2020) | Revenue (est.) $9.9b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods ₹95.5b (FY, 2026) | Cost of goods N/A | Cost of goods $2.4b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit ₹195b (FY, 2026) | Gross profit $4.5b (FY, 2020) | Gross profit $7.5b (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income ₹38.7b (FY, 2026) | Net income N/A | Net income $1.3b (FY, 2025) |
Operating ⚠ | |||||
Trademark Applications | Trademark Applications N/A | Trademark Applications 3 (Feb, 2021) | Trademark Applications N/A | Trademark Applications 1 (Dec, 2020) | Trademark Applications N/A |
For sources of this data, please see the company profile
View Company Profiles
Immunai
HQ
New York, US
Employees
187↑ 3% increase
Immunai is a biotechnology company specializing in immune cell data analysis for drug development.
View companyCipla
HQ
Mumbai, IN
Employees
27,764
Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
View companyBiogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View company